Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption

Autor: Ananworanich, J, Melvin, D, Amador, Jt, Childs, T, Medin, G, Boscolo, V, Compagnucci, A, Kanjanavanit, S, Montero, S, Gibb, Dm, PENTA 11 Study Group including Aboulker, J, Babiker, A, Belfrage, E, Bernardi, S, Bologna, R, Burger, D, Butler, K, Castelli Gattinara, G, Castro, H, Clayden, P, Cressey, T, Darbyshire, Jh, Debré, M, de Groot, R, della Negra, M, di Biagio, A, De Rossi, A, Duicelescu, D, Faye, A, Giaquinto, C, Giacomet, V, Grosch Wörner, I, Hainault, M, Klein, N, Lallemant, M, Levy, J, Lyall, H, Marczynska, M, Marques, L, Mardarescu, M, Mellado Peña MJ, Nadal, D, Nastouli, E, Naver, L, Niehues, T, Peckham, C, Pillay, D, Popieska, J, Ramos Amador JT, Rojo Conejo, P, Rosado, L, Rosso, R, Rudin, C, Scherpbier, Hj, Sharland, M, Stevanovic, M, Thorne, C, Tovo, Pier Angelo, Tudor Williams, G, Turkova, A, Valerius, N, Volokha, A, Walker, As, Welch, S, Wintergerst, U, Aboulker, Jp, Burger, Dm, Green, H, Harper, L, Mofenson, L, Moye, J, Saïdi, Y, Cressey, Tr, Jacqz Aigrain, E, Khoo, S, Regazzi, M, Tréluyer, Jm, Ngo Giang Huong, N, Muñoz Fernandez MA, Hill, C, Lepage, P, Pozniak, A, Vella, S, Chêne, G, Vesikari, T, Hadjou, G, Léonardo, S, Riault, Y, Bleier, J, Buck, L, Duong, T, Farrelly, L, Forcat, S, Harrison, L, Horton, J, Johnson, D, Taylor, C, Chalermpantmetagul, S, Peongjakta, R, Khamjakkaew, W, Than in at, K, Chailert, S, Jourdain, G, Le Coeur, S, Floret, D, Costanzo, P, Le Thi TT, Monpoux, F, Mellul, S, Caranta, I, Boudjoudi, N, Firtion, G, Denon, M, Charlemaine, E, Picard, F, Hellier, E, Heuninck, C, Damond, F, Alexandre, G, Tricoire, J, Antras, M, Lachendowier, C, Nicot, F, Krivine, A, Rivaux, D, Notheis, G, Strotmann, G, Schlieben, S, Rampon, O, Zanchetta, M, Ginocchio, F, Viscoli, C, Martino, A, Pontrelli, G, Baldassar, S, Concato, C, Mazza, A, Rossetti, G, Dobosz, S, Oldakowska, A, Popielska, J, Kaflik, M, Stanczak, J, Stanczack, G, Dyda, T, Kruk, M, González Tomé MI, Delgado García, R, Fernandez Gonzalez MT, Mellado Peña, M, Martín Fontelos, P, Garcia Mellado MI, Medina, Af, Ascencion, B, Garcia Bermejo, I, Navarro Gomez DM, Saavedra, J, Prieto, C, Jimenez, Jl, Garcia Torre, A, de José Gómez MI, García Rodriguez MC, Moreno Pérez, D, Núñez Cuadros, E, Asensi Botet, F, Otero Reigada, C, Pérez Tamarit MD, Vilalta, R, Molina Moreno JM, Rainer, T, Schupbach, J, Rutishauser, M, Bunupuradah, T, Butterworth, O, Phasomsap, C, Prasitsuebsai, W, Chuanjaroen, T, Jupimai, T, Ubolyam, S, Phanuphak, P, Puthanakit, T, Pancharoen, C, Mai, C, Namwong, T, Punsakoon, W, Payakachat, S, Chutima, D, Raksasang, M, Foster, C, Hamadache, D, Campbell, S, Newbould, C, Monrose, C, Abdulla, A, Walley, A, Patel, D, Kaye, S, Seery, P, Rankin, A, Wildfire, A, Novelli, V, Shingadia, D, Moshal, K, Flynn, J, Clapson, M, Allen, A, Spencer, L, Rackstraw, C, Ward, B, Parkes, K, Depala, M, Jacobsen, M, Poulsom, H, Barkley, L, Miah, J, Lurie, P, Keane, C, Mcmaster, P, Phipps, M, Orendi, J, Farmer, C, Liebeschuetz, S, Sodeinde, O, Wong, S, Bostock, V, Heath, Y, Scott, S, Gandhi, K, Lewis, P, Daglish, J, Miles, K, Summerhill, L, Subramaniam, B, Weiner, L, Famiglietti, M, Rana, S, Yu, P, Roa, J, Puga, A, Haerry, A.

Publikováno v: AIDS (London, England), 30(7), 1075-1081. Lippincott Williams and Wilkins
Aids, 30, 1075-81
Aids, 30, 7, pp. 1075-81

Item does not contain fulltext OBJECTIVE: Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afaf1c4843353c622b0406480f65a2fd
http://hdl.handle.net/11577/3233528

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial

Autor: Aboulker Jp, JH Darbyshire, Pierre-Marie Girard, Ruth L. Goodall, Dianne Carey, Marco Floridia, Salzberger B, MH Hooker, A Babiker, Patrick Yeni, Meiffredy, Anne M Mijch, David A. Cooper

Publikováno v: The Lancet. 368:287-298

INITIO Trial International Co-ordinating Committee* Summary Background Antiretroviral therapy has greatly reduced HIV mortality and morbidity. However, the best sequence of regimens and implications of initial regimen for long-term therapeutic succes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aa398433d15205339b27f3af1b72e74
https://doi.org/10.1016/s0140-6736(06)69074-0

Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial.

Autor: Lutsar I; Institute of Translational Medicine, University of Tartu, Tartu, Estonia., Chazallon C; INSERM SC10-US19, Villejuif, France., Trafojer U; Women's and Children's Health Department, Neonatal Intensive Care Unit, Azienda Ospedaliera-University of Padua, Padua, Italy., de Cabre VM; INSERM SC10-US19, Villejuif, France., Auriti C; Department of Neonatology, Neonatal Intensive Care Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Bertaina C; University Department of Paediatrics, Immunological and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Calo Carducci FI; University Department of Paediatrics, Immunological and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Canpolat FE; Sağlık Bilimleri Üniversitesi, Zekai Tahir Burak Kadın Sağlığı Eğitim ve Araştırma Hastanesi, Neonatoloji Kliniği, Ankara, Turkey., Esposito S; Pediatric Highly Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy., Fournier I; INSERM SC10-US19, Villejuif, France., Hallik M; Department of Intensive Care, Tallinn Children's Hospital, Tallinn, Estonia., Heath PT; Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom., Ilmoja ML; Institute of Translational Medicine, University of Tartu, Tartu, Estonia.; Department of Intensive Care, Tallinn Children's Hospital, Tallinn, Estonia., Iosifidis E; 3rd Department of Pediatrics, Faculty of Medicine, Infectious Diseases Unit, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece., Kuznetsova J; Tartu University Hospital, Clinic of Anaesthesiology and Intensive Care, Tartu, Estonia., Meyer L; INSERM SC10-US19, Villejuif, France., Metsvaht T; Institute of Translational Medicine, University of Tartu, Tartu, Estonia.; Tartu University Hospital, Clinic of Anaesthesiology and Intensive Care, Tartu, Estonia., Mitsiakos G; 2nd Department of Neonatology, Faculty of Medicine, Aristotle University School of Health Sciences, Papageorgiou Hospital, Thessaloniki, Greece., Pana ZD; 3rd Department of Pediatrics, Faculty of Medicine, Infectious Diseases Unit, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece., Mosca F; Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy., Pugni L; Neonatal Intensive Care Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy., Roilides E; 3rd Department of Pediatrics, Faculty of Medicine, Infectious Diseases Unit, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece., Rossi P; University Department of Paediatrics, Immunological and Infectious Disease Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy., Sarafidis K; 1st Department of Neonatology, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece., Sanchez L; Hospital Universitario Infantil LA PAZ- H. Carlos III, Madrid, Spain., Sharland M; Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom., Usonis V; Faculty of Medicine, Vilnius University, Vilnius, Lithuania., Warris A; MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom., Aboulker JP; INSERM SC10-US19, Villejuif, France., Giaquinto C; Department of Women's and Children's Health, University of Padova, Padova, Italy.

Publikováno v: PloS one [PLoS One] 2020 Mar 04; Vol. 15 (3), pp. e0229380. Date of Electronic Publication: 2020 Mar 04 (Print Publication: 2020).

Zidovudine Resensitization and Dual HIV-1 Resistance to Zidovudine and Lamivudine in the Delta Lamivudine Roll-Over Study

Autor: I. Carriere, Chanzy B, Buffet-Janvresse C, Bernard Masquelier, Jacques Izopet, Denayrolles M, Françoise Ferchal, Françoise Brun-Vézinet, Aboulker Jp, Annick Ruffault, Schmitt Mp, Diane Descamps, Patrick Yeni, Esther Race, Hervé Fleury, Gilles Collin

Publikováno v: Antiviral Therapy. 4:69-77

Objective To study zidovudine resensitization and dual resistance to zidovudine/lamivudine in HIV-1 isolates from nucleoside reverse transcriptase (RT) inhibitor-experienced patients during selective pressure exerted by zidovudine/lamivudine combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe44e0472d835729f6854e6514a61c87
https://doi.org/10.1177/135965359900400203

Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial

Autor: Lutsar, I, Trafojer, Um, Heath, Pt, Metsvaht, T, Standing, J, Esposito, S, de Cabre VM, Oeser, C, Aboulker, Jp, Giaquinto, Carlo, the NeoMero Consortium

Publikováno v: Trials, Vol 12, Iss 1, p 215 (2011)
Trials, London : BioMed Central Ltd, 2011, Vol. 12, art. no. 215, [9 p.]
Trials; Vol 12
Trials
Trials, 2011, 12 (1), pp.215. ⟨10.1186/1745-6215-12-215⟩
Trials, BioMed Central, 2011, 12 (1), pp.215. ⟨10.1186/1745-6215-12-215⟩

International audience; ABSTRACT: BACKGROUND: Late onset neonatal sepsis (LOS) with the mortality of 17 to 27% is still a serious disease. Meropenem is an antibiotic with wide antibacterial coverage. The advantage of it over standard of care could be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec4926a094908d3a434d67019a86777
http://hdl.handle.net/11577/2806355